Showing results (231-240 of 553) with videos related to

Sort By:
Pageof 56
Radiology|May 1, 1988
In-111-labeled white blood cell uptake in noninfected closed fracture in humans: prospective studyD Van Nostrand, S H Abreu, J J Callaghan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2001
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanomaM B Atkins, B Redman, J Mier, et al.
Endocrine Research|November 1, 1996
Adrenarche is associated with decreased 3 beta-hydroxysteroid dehydrogenase expression in the adrenal reticularisJ S Gell, B Atkins, L Margraf, et al.
BMC Microbiology|December 3, 2010
The heme sensing response regulator HssR in Staphylococcus aureus but not the homologous RR23 in Listeria monocytogenes modulates susceptibility to the antimicrobial peptide plectasinLine E Thomsen, Caroline T Gottlieb, Sanne Gottschalk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancerM J Robertson, C Cameron, M B Atkins, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokinesJ Dutcher, M B Atkins, K Margolin, et al.
Cancer Research|May 1, 1992
Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastasesJ B Tatro, Z Wen, M L Entwistle, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trialsM B Atkins, J Dutcher, G Weiss, et al.
The Journal of Biological Chemistry|November 25, 2020
Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosisAnna V Mathew, Lixia Zeng, Kevin B Atkins, et al.
Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.
Pageof 56